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he transmembrane protein amyloid-
 
 
 
 precursor
protein (APP) and the vesicle-associated protein
c-Jun NH
 
2
 
-terminal kinase–interacting protein-1
(JIP-1) are transported into axons by kinesin-1. Both pro-
teins may bind to kinesin-1 directly and can be trans-
ported separately. Because JIP-1 and APP can interact,
kinesin-1 may recruit them as a complex, enabling their
cotransport. In this study, we tested whether APP and JIP-1
are transported together or separately on different vesi-
cles. We found that, within the cellular context, JIP-1
preferentially interacts with Thr
 
668
 
-phosphorylated APP
(pAPP), compared with nonphosphorylated APP. In neu-
T
 
rons, JIP-1 colocalizes with vesicles containing pAPP and
is excluded from those containing nonphosphorylated
APP. The accumulation of JIP-1 and pAPP in neurites re-
quires kinesin-1, and the expression of a phosphomimetic
APP mutant increases JIP-1 transport. Down-regulation of
JIP-1 by small interfering RNA speciﬁcally impairs trans-
port of pAPP, with no effect on the trafﬁcking of non-
phosphorylated APP. These results indicate that the
phosphorylation of APP regulates the formation of a
pAPP–JIP-1 complex that accumulates in neurites inde-
pendent of nonphosphorylated APP.
 
Introduction
 
In neurons, membrane-bound cargoes are transported into axons
by kinesin motors such as kinesin-1 (Muresan, 2000). Because
the rate of the delivery of proteins into axons should meet the
needs of the individual proteins at the destination, the forma-
tion of the transport vesicle and recruitment of the required
kinesin motor have to be highly regulated. This study addresses
the regulation of the axonal transport of two kinesin-1 cargoes,
the amyloid-
 
 
 
 precursor protein (APP) and the c-Jun NH
 
2
 
-
terminal kinase (JNK)–interacting protein-1 (JIP-1).
Kinesin-1 is recruited to its vesicular cargoes by trans-
membrane or cytoplasmic vesicle–associated proteins that in-
teract with either the kinesin light chain (KLC) or kinesin
heavy chain (KHC). Among the proposed kinesin-1 cargo link-
ers are APP and JIP-1. APP, the precursor of the amyloid-
 
 
 
peptide that forms the senile plaques in Alzheimer’s disease, is
a type-I transmembrane protein (Selkoe, 1998), whereas JIP-1
is a scaffolding protein for the JNK signaling complex that, al-
though not an integral membrane protein, is associated with in-
tracellular membranes (Whitmarsh et al., 1998). APP and JIP-1
have been reported to interact with the tetratricopeptide repeat
(TPR) domain of KLC (Kamal et al., 2000; Whitmarsh et al.,
2001; Verhey et al., 2001), suggesting that each of them can be
transported by kinesin-1 as an independent cargo. JIP-1 can
also bind to APP via its phosphotyrosine-binding domain and
the YENPTY-containing site in the cytoplasmic tail of APP
(Matsuda et al., 2001; Scheinfeld et al., 2002; Taru et al.,
2002). Upon exogenous expression, this complex recruits ex-
pressed KLC, suggesting the possibility of the cotransport of
APP bound to JIP-1 (Inomata et al., 2003). Whether in normal
conditions APP and JIP-1 are transported as a complex or inde-
pendently is not known, and is certainly determined by the type
of interactions that the endogenous proteins establish both be-
tween themselves and with kinesin-1.
Starting from the premise that the in vivo interaction of
APP with JIP-1 has to be regulated, we tested whether the phos-
phorylation of residues in the cytoplasmic domain of APP plays
any role in the formation of the APP–JIP-1 complex. Recent
studies have focused on the phosphorylation of Thr
 
668
 
 (human
APP695 isoform numbering), which has been implicated in neu-
ronal differentiation (Ando et al., 1999), APP processing (Lee
et al., 2003), and the accumulation of an APP cytoplasmic
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fragment in the nucleus (Muresan and Muresan, 2004). Thr
 
668
 
-
phosphorylated APP (pAPP) is concentrated at neurite endings
(Ando et al., 1999; Muresan and Muresan, 2005), suggesting that
phosphorylation might also target pAPP into neurites.
Using the catecholaminergic, central nervous system–
derived neuronal cell line CAD, we investigated whether APP
and JIP-1 are transported on the same carrier vesicle or indepen-
dently, on distinct vesicles. We focused on studying the trans-
port of endogenous proteins under physiological conditions, an
experimental approach intended to avoid the many pitfalls of
exogenous protein expression. We found that JIP-1 preferen-
tially interacts with pAPP and is cotransported with pAPP into
neuronal processes by kinesin-1. We also discovered that non-
phosphorylated APP is transported independently of pAPP and
JIP-1. These findings point to a role for APP phosphorylation in
the transport of JIP-1, and possibly in regulating signaling cas-
cades assembled on this scaffolding protein.
 
Results
 
JIP-1 and APP reside on distinct 
vesicles throughout neuronal processes
 
JIP-1 and APP are cargoes for kinesin-1 that could theoreti-
cally be transported into neuronal processes, either indepen-
dently or as a complex. To test the interdependence of transport
of endogenous JIP-1 and APP, we set out to determine if these
two proteins localize on separate carrier vesicles along the neu-
ronal processes, where most vesicles move anterogradely en
route to the neurite terminals, or on the same carrier vesicle
(Fig. S1, available at http://www.jcb.org/cgi/content/full/
jcb.200502043/DC1; Kaether et al., 2000; Stamer et al., 2002;
unpublished data). To this end, we performed high resolution,
double labeling immunocytochemistry for JIP-1 and APP in
the CAD neuronal cell line.
The specificity of the antibodies used for the immunolocal-
ization of JIP-1 and APP was verified by Western blots of rat
brain lysate. Antibodies to JIP-1 detected two polypeptides
(Fig. S2 A, available at http://www.jcb.org/cgi/content/full/
jcb.200502043/DC1) that correspond to the previously identified
forms of endogenous JIP-1 (Meyer et al., 1999). For APP we
tested antibodies 22C11 and 4G8, which are frequently used for
the detection of total APP (Kamal et al., 2000; Lazarov et al.,
2005; Lee et al., 2005). Each of them labeled a band with mobil-
ity that was characteristic of APP (Fig. S2 A). However, in this
work, we mostly used the antibody 4G8 for immunocytochemistry
because 22C11 may cross-react with the amyloid precursor-like
protein 2, a protein related to APP (Wasco et al., 1993).
CAD cells have proven suitable for studying the intracellu-
lar traffic powered by kinesins (Verhey et al., 2001; Muresan and
Muresan, 2005). When cultured in serum-free medium, CAD
cells differentiate and gain the biochemical and morphological
characteristics of primary neurons in culture (Qi et al., 1997),
with thin processes and terminals where transport vesicles and
their associated proteins can be resolved using high power fluo-
rescence microscopy. In these cells, transport of APP (see next
section) and JIP-1 (Verhey et al., 2001) is kinesin-1 dependent,
and the global localization of these proteins (Fig. S2, B and C) is
identical to that in neurons (Yamazaki et al., 1995; Yasuda et al.,
1999). We found that JIP-1 immunolabeling (Fig. 1, A–F) is
mostly punctuate, suggesting that endogenous JIP-1 is largely
associated with vesicles. As previously reported for other neurons
(Yasuda et al., 1999), in CAD cells JIP-1 appeared concentrated
at the terminals of processes (Fig. S2 B and Fig. 1, A and D).
Similar to JIP-1, APP was found in the cell body and processes,
in a punctuate appearance typical of vesicle proteins (Fig. 1, A–F).
Importantly, the majority of APP (
 
 
 
80%) was not localized to
vesicles that contained JIP-1, a result that was consistently
obtained using several antibodies to APP and JIP-1. This result
was confirmed in primary cultures of cortical neurons that
closely reproduce the distribution of these proteins in neurons in
situ (Fig. 1, G–L). Based on this set of data, we conclude that
only a small fraction of APP is cotransported with JIP-1.
 
JIP-1 colocalizes and interacts with 
pAPP rather than with 
nonphosphorylated APP
 
We focused on characterizing the fraction of APP that colocal-
izes with JIP-1. We observed that the accumulation of JIP-1 at
Figure 1. Colocalization of JIP-1 with pAPP in neuronal processes. CAD
cells (A–F and M–Y) and cortical neurons (G–L, Z– ) were double labeled
for JIP-1 and either total APP (antibody 4G8; A–L) or pAPP (M– ). (A–L)
The majority of total APP (A–F, red; G–L, green) is present in vesicles dis-
tinct from those carrying JIP-1 (A–F, green; G–L, red). (B and H) Enlarge-
ments of the boxed areas in A and G. (D and E) Single color enlargements
of the process terminal shown in A. Similarly, I–L represent single color
enlargements of regions from the distal and proximal neurite shown in G
and H to reveal the distinct distribution of JIP-1 and APP along the neurite.
(G, H, J, and L) Arrows mark the ends of corresponding segments. (M– )
JIP-1 (M–Y and  , green;  , white) colocalizes extensively with pAPP (M–Y
and  , red; Z, white) throughout the processes (P–R) and at their terminals
(S– ). Bars: (A–L) 5  m; (M–O) 20  m; (P– ) 10  m. 
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the terminals (Fig. 1, A and G) is strikingly similar to that re-
ported for pAPP (Ando et al., 1999). This raised the question of
whether JIP-1 might be carried into processes along with
pAPP. To test this hypothesis, we began by studying the distribu-
tion of pAPP in CAD cells with an antibody to a phosphorylated
polypeptide from a region around pThr
 
668
 
 in the cytoplasmic
domain of APP. We verified the specificity of this antibody
toward pAPP in immunoblots of rat brain extract. A single
major band with electrophoretic mobility corresponding to
mature APP was detected (Fig. S2 A). In immunocytochemistry,
the antibody produced a staining (Fig. S2 D) similar to that re-
ported for pAPP in neurons (Ando et al., 1999; Iijima et al.,
2000). This staining was completely abolished by competition
with the phosphorylated polypeptide from the cytoplasmic do-
main of APP (Fig. S2, G and H), but was not affected by the
corresponding nonphosphorylated polypeptide (Fig. S2, E
and F). These results confirmed the specificity of this antibody
for pAPP. Next, we used these antibodies for dual labeling of
pAPP and JIP-1 in CAD cells and cortical neurons. As shown
in Fig. 1 (M–
 
 
 
), endogenous pAPP colocalized extensively
with JIP-1, both at the terminals and throughout the processes.
Quantitative measurements of the overlap indicated that 
 
 
 
85%
of pAPP colocalized with JIP-1. These results support the notion
that JIP-1 and pAPP mostly reside on the same vesicle popula-
tion, along the neurites and at neurite terminals.
The molecular basis of this result might be the direct inter-
action between pAPP and JIP-1, which is a known APP-binding
protein (Matsuda et al., 2001). Probing for such an interaction in
CAD cells proved difficult because of the small amounts of en-
dogenous pAPP and JIP-1. Therefore, we prepared extracts
from COS-1 cells transfected with FLAG-tagged JIP-1 and
performed in vitro pull-down assays on biotinylated polypep-
tides comprising the entire cytoplasmic domain of APP, phos-
phorylated or not, at the residue corresponding to Thr
 
668
 
 (Fig.
2, A and B). Polypeptides were collected on streptavidin-
Sepharose and analyzed for bound JIP-1 by immunoblotting
with antibodies to FLAG. Although JIP-1 interacted with both
the phosphorylated and nonphosphorylated forms, at equal
amounts of peptides (Fig. 2 B, Ponceau S) it was preferentially
captured by the phosphorylated peptide (Fig. 2 B). This result
was reproduced by ELISA analysis (Fig. 2 C). In addition,
ELISA showed that, at high concentration, JIP-1 binds indis-
criminately to the phosphorylated and nonphosphorylated
peptides (Fig. 2 C, left). We note that ELISA assays were con-
ducted in the presence of cytosol, using low concentrations of
JIP-1–FLAG expressed in HEK 293 cells.
Unlike JIP-1, in the peptide capture assay, JIP-2 bound
equally well to the peptides regardless of their state of phos-
phorylation (Fig. 2 B). Using ELISA, we also confirmed that
Fe65, which is an APP-binding protein unrelated to the JIPs,
preferentially bound to the nonphosphorylated APP peptide (Fig.
2 C, right; Ando et al., 2001), which validated our ELISA proto-
col. The interaction between JIP-1 and full-length pAPP was fur-
ther tested by immunoprecipitation from extracts of CAD cells
that expressed ectopic JIP-1–FLAG and human APP695. Under
these conditions, a fraction of the expressed APP becomes phos-
phorylated (Muresan and Muresan, 2005). As shown in Fig. 2 D,
only a small fraction of the total mature APP coprecipitated with
JIP-1. However, a large proportion of the mature, fully glyco-
sylated form of pAPP bound to JIP-1. This result suggests that
JIP-1 preferentially associates with pAPP, and not with its non-
phosphorylated form. This binding preference for pAPP at low
JIP-1 concentrations, although small, may prevail under in vivo
conditions and contribute to the colocalization of JIP-1 with
pAPP (Fig. 1). Thus, phosphorylation of APP may facilitate the
recruitment of JIP-1 to vesicles.
 
JIP-1 and pAPP are cotransported by 
kinesin-1 to neurite terminals
 
Based on the colocalization and preferential interaction of JIP-1
with pAPP, we propose a model for the transport of these pro-
Figure 2. Biochemical analysis of JIP-1 interaction with nonphosphory-
lated and phosphorylated APP. (A) SDS-PAGE separation of synthetic,
biotinylated, phosphorylated (pAPPCD), and nonphosphorylated (APPCD)
polypeptides encompassing the APP cytoplasmic domain (Tris-tricine gel).
Peptides were detected on the same gel, but the lanes are presented in
separate boxes to indicate that the contrast was adjusted differently for
each lane. This was done to demonstrate the purity of the peptides rather
than their relative amounts. (B) Pull-down experiment done with the polypep-
tides shown in A. Equal amounts of the two polypeptides (Ponceau S) were
incubated with lysates of COS-1 cells transfected with FLAG-tagged JIP-1
or JIP-2 and collected on streptavidin-Sepharose. Copurified JIPs were de-
tected by immunoblotting with antibodies to the FLAG tag (marked JIP-1
and JIP-2). Note that JIP-1, but not JIP-2, binds preferentially to pAPPCD.
Densitometric analysis of blots showed that JIP-1 binding to APPCD is 30–
40% lower than to pAPPCD. A control lane (Beads) shows residual binding
of JIP-1–FLAG to beads in the absence of added polypeptide. The anti-
pAPP antibody detects the phosphorylated, but not the nonphosphory-
lated, polypeptide in the pulled-down material (Anti-pAPP). (C) Differential
binding of JIP-1 and Fe65 to phosphorylated and nonphosphorylated APP
polypeptides (ELISA). Streptavidin-coated ELISA plates, preadsorbed with
biotinylated APPCD or pAPPCD, were incubated with increasing concentra-
tions of cytosol (expressed as percentages of the total incubation mixture;
see Materials and methods) from HEK293 cells transfected with either JIP-1–
FLAG or Fe65-myc. Bound proteins were detected colorimetrically, using
alkaline phosphatase–labeled antibodies to the tags. Error bars represent
SEM (n   3). (D) Coprecipitation of phosphorylated and nonphosphory-
lated APP with JIP-1. CAD cells were transfected separately with human
APP695 and with JIP-1–FLAG; the two cell extracts were mixed and incu-
bated overnight. Mixtures were immunoprecipitated with an anti-FLAG an-
tibody, and immunoprecipitated material was analyzed by immunoblotting
with antibodies to total APP, pAPP, and FLAG. The three polypeptides de-
tected with the anti-APP antibody correspond to immature and mature
forms of APP695 (arrow points to the fully glycosylated form of APP).
(right, No JIP-1) Nonspecific binding of APP and pAPP to beads, in the
absence of JIP-1–FLAG-containing cytosol, was low. 
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teins into neuronal processes where JIP-1 mediates recruitment
of kinesin-1 to pAPP in the cell body, resulting in the transport
of the pAPP–JIP-1 complex to the terminals. The model predicts
the following: (1) pAPP and JIP-1 colocalize with kinesin-1 in
neurites; (2) transport of pAPP—similar to that of JIP-1—is
dependent on kinesin-1; (3) phosphorylation of APP occurs in
the cell body, before kinesin-1 recruitment and initiation of
transport; (4) recruitment of kinesin-1 to pAPP and transport of
pAPP are enhanced by JIP-1; (5) transport of JIP-1 into neurites
is enhanced by APP phosphorylation; and (6) down-regulation
of JIP-1 expression reduces transport of pAPP into neurites.
We tested these suppositions as follows.
First, we tested if, consistent with its transport by a kine-
sin motor, pAPP colocalizes with microtubules throughout
the processes of CAD cells (Fig. S3, A–D, available at http://
www.jcb.org/cgi/content/full/jcb.200502043/DC1). Further,
pAPP colocalizes with KHC (Fig. S3, H–K) and KLC (Fig. S3,
L–N) of kinesin-1, but not with another kinesin (Fig. S3, E–G).
In these experiments, the KLCs were detected with the anti-
body 63-90, which preferentially recognizes the nonphos-
phorylated, cargo-bound form of KLCs (Pigino et al., 2003).
This result is important because it suggests that pAPP is associ-
ated with kinesin-1 at the neurite terminals, most likely a con-
sequence of prior active transport toward this destination.
Second, to test whether transport of pAPP requires kine-
sin-1, we used a dominant-negative construct that specifically
uncouples this kinesin from the cargoes that bind to the KLCs
(Verhey et al., 2001). When we expressed the tagged, kinesin-1
dominant-negative domain HA-KLC-TPR in CAD cells, trans-
port of pAPP was significantly reduced: 
 
 
 
10% of the trans-
fected cells showed pAPP at their terminals (Fig. 3, A–H). By
comparison, 
 
 
 
85% of the cells that overexpressed a TPR domain
unrelated to that of KLC (that of protein phosphatase 5 [PP5])
showed unperturbed accumulation of pAPP at their terminals
(Fig. 3, I and J). These results support our hypothesis that accu-
mulation of JIP-1 and pAPP at the terminals requires kinesin-1.
Third, a closer examination of the KLC-TPR–expressing
cells revealed a buildup of pAPP-containing vesicles in the cell
bodies at the emergence of the processes (Fig. 3, A and D, arrow-
heads). This is consistent with impaired transport of pAPP gener-
ated in the cell body. Like pAPP, JIP-1 also accumulated in the
cell body of cells transfected with KLC-TPRs (Fig. 3, K and L),
indicating that transport of pAPP and JIP-1 are regulated by kine-
sin-1 in a similar manner. Additional data in support of APP phos-
phorylation in the cell body is provided by immunocytochemistry
experiments showing that pAPP associated with vesicular struc-
tures in the Golgi region of CAD cells, whether they were non-
transfected (Fig. 3, M and N) or transfected with APP-YFP (Fig. 3,
O and P). Together, these observations suggest that an interaction
with the KLCs of kinesin-1 is required for the transport of pAPP-
containing vesicles from the cell body into processes.
Using a similar experimental strategy, we also confirmed
that the delivery of total APP into processes largely relies on
kinesin-1 (Yamazaki et al., 1995; Kaether et al., 2000), and
probably requires an interaction of the APP-containing cargo
with the KLCs (Fig. S4, available at http://www.jcb.org/cgi/
content/full/jcb.200502043/DC1).
Fourth, because our model states that JIP-1 and pAPP are
transported as a complex, we tested if increased availability of
JIP-1 facilitates transport of pAPP to neurite terminals. First,
we determined biochemically whether the recruitment of ki-
nesin-1 to pAPP is enhanced by increased amounts of JIP-1.
We transfected CAD cells with a mutated human APP695 that
mimics pAPP, called APP-Thr668Glu (Ando et al., 1999).
Lysates of these cells were mixed with extracts of CAD cells
that were JIP-1 transfected or nontransfected (control) and
incubated to allow the formation of APP-Thr668Glu–JIP-1
complexes. Equal amounts of squid kinesin-1 were then
added to the incubation mixtures. Putative complexes con-
taining APP-Thr668Glu–JIP-1–kinesin-1 were immunoprecipi-
tated and analyzed by immunoblotting. For immunoprecipitation,
Figure 3. Localization of pAPP at neurite terminals requires kinesin-1.
(A–L) Localization of pAPP (A–J) and JIP-1 (K and L) in CAD cells overex-
pressing the tagged, kinesin-1 dominant-negative construct, HA-KLC-TPR
(A–H, K, and L), or the control construct, HA-PP5-TPR (I and J). Two exam-
ples show the effect of HA-KLC-TPR expression on pAPP localization (A–C
and D–H). Note that pAPP and JIP-1 accumulate in the cell body of cells
transfected with HA-KLC-TPR (arrowheads) and are not detected at the ter-
minals of their processes (long arrows). In contrast, pAPP and JIP-1 localize
to the neurite terminals in nontransfected cells (short arrows). Localization
of pAPP is not affected in cells transfected with HA-PP5-TPR (compare short
with long arrows in I and J). No pAPP accumulation in the cell body of the
transfected cell is seen (I and J, arrowheads). (F–H) Enlarged images of
the neurite shown in D and E. (M–P) pAPP can be detected in the Golgi
area in CAD cells. (M and N) Vesicular localization of endogenous pAPP
in the Golgi region (arrow) of a CAD cell. (O and P) In cells transfected
with APP695, pAPP is found throughout the processes and in the cell body
(P, arrows). (O) Image depicts total APP. (C, H, and N) Phase-contrast
micrographs. Bars, 20  m. 
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we used an antibody to human APP that recognizes only ectop-
ically expressed, phosphomimetic human APP and does not
cross-react with the endogenous mouse APP; therefore, we im-
munoprecipitated only complexes containing phosphomimetic
APP. Although binding of kinesin-1 to APP-Thr668Glu was
low and variable in the absence of JIP-1, we consistently
found increased amounts of kinesin-1 coprecipitating with
APP-Thr668Glu from mixtures that contained JIP-1 (Fig. 4 A,
top). Under the same experimental conditions that detected in-
creased kinesin-1 recruitment to APP-Thr668Glu, we did not
see any reproducible change in the amount of coprecipitated ki-
nesin-1 when using lysates of CAD cells transfected with the
nonphosphorylatable APP-Thr668Ala mutant (Fig. 4 A, bottom).
These results suggest that JIP-1 preferentially facilitates re-
cruitment of kinesin-1 to pAPP.
We also tested whether increased in vivo expression of
JIP-1 in CAD cells resulted in enhanced transport of endogenous
pAPP to neurite terminals. Owing to the dominant-negative
effect of JIP-1 overexpression on JNK activity toward its sub-
strates, high levels of JIP-1–FLAG decreased the overall pro-
duction of pAPP (Muresan and Muresan, 2005) and prevented
direct evaluation of the role of JIP-1 in the transport of pAPP.
Therefore, we limited our analysis to those cells that expressed
low levels of JIP-1–FLAG (see typical examples of such cells
in Fig. 4, B–H). In these conditions, JIP-1–FLAG was largely
localized to neurite terminals (Fig. 4, B–H), a distribution that
closely resembled that of endogenous JIP-1 (see Fig. S5 A).
Notably, the amount of pAPP that accumulated at the neurite
endings was significantly increased (Fig. 4, B–H). We esti-
mated that 80–90% of the CAD cells that expressed low levels
of JIP-1–FLAG showed increased amounts of pAPP at neurite
terminals compared with neighboring, nontransfected cells.
This percentage dropped to 
 
 
 
30% for cells transfected with
myc-tagged Fe65, a protein that binds to APP at the same site
as JIP-1. In addition, at neurite terminals, pAPP extensively
colocalized with JIP-1–FLAG but not with Fe65-myc (colocal-
ization coefficients 91 
 
 
 
 5 vs. 23 
 
 
 
 11; mean 
 
 
 
 SD; Fig. 4,
compare B–H with I–K). These results are consistent with in-
creased transport of pAPP facilitated by the recruitment of
kinesin-1 via JIP-1.
Fifth, conversely, we tested whether an increased amount
of pAPP within cells led to increased transport of JIP-1. We
transfected CAD cells with human APP-Thr668Glu that mim-
ics pAPP and labeled it with the antibody 6E10 that preferen-
tially recognizes human APP and not endogenous mouse APP
(Fig. 4 L). Compared with the nontransfected cells (Fig. 4, L
and M, short arrows), at moderate levels of expression of
APP-Thr668Glu, endogenous JIP-1 appeared more efficiently
accumulated at the tips of processes, and colocalized with
APP-Thr668Glu (Fig. 4, L and M, long arrows). Overall, in
 
 
 
90% of transfected cells, we detected a strict correlation be-
tween the amount and distribution of exogenously expressed
APP-Thr668Glu and JIP-1 at process terminals (Fig. 4, L–O
and V [top]). No such correlation was seen in cells expressing
low to moderate levels of wild-type APP (Fig. 4, S–U) or non-
phosphorylatable APP-Thr668Ala mutant (Fig. 4, P–R and
V, bottom). In addition, as shown in Fig. 4 (L and M), cells
transfected with APP-Thr668Glu extended unusually long
processes, a result that is consistent with a proposed role of
pAPP in neurite extension (Ando et al., 1999; Muresan and
Muresan, 2005). At high levels of expression, as predicted by
our biochemical data (Fig. 2 C), all APP forms promoted in-
creased JIP-1 transport, presumably a nonspecific result of
overloading the system. Together, these data suggest that JIP-1
Figure 4. JIP-1 facilitates the binding of kinesin-1 to pAPP and the trans-
port of pAPP. (A) Coprecipitation of kinesin-1 with constitutively phosphor-
ylated, but not nonphosphorylatable APP, is enhanced by JIP-1. Lysates of
CAD cells transfected with APP-Thr668Glu (APP(T-E)) or APP-Thr668Ala
(APP(T-A)) were mixed with lysates of CAD cells transfected with JIP-1–
FLAG ( ) or of nontransfected ( ) CAD cells. Squid kinesin-1 was added
to the mixtures, and APP was immunoprecipitated with an antibody to
human APP (mAbP2-1). Immunoprecipitated material was tested for the
presence of KHC and KLC by immunoblotting. APP blots showed equal
amounts of immunoprecipitated APP. Densitometric analysis of blots
showed that, in the case of APP-Thr668Glu, approximately three times
more kinesin-1 is coprecipitated from mixtures that contained JIP-1 ( ).
(B–K) CAD cells transfected with FLAG-tagged JIP-1 (B–H) or myc-tagged
Fe65 (I–K) were double labeled for endogenous pAPP (B, E, G, and I) and
the tag (C, F, H, and J). Note that the cells expressing JIP-1–FLAG show an
increased amount of pAPP at the process terminals, which colocalizes with
the expressed JIP-1 (B–H, long arrows). In contrast, pAPP does not colo-
calize with Fe65-myc (I–K). (B, E, and D) Short arrows point to the termi-
nals of nontransfected cells. (L–V) Constitutively phosphorylated APP
(APP-Thr668Glu), but not nonphosphorylatable APP (APP-Thr668Ala),
promotes a more efficient transport of endogenous JIP-1 into CAD cell
processes. Images show the localization of endogenous JIP-1 and exoge-
nously expressed APP in CAD cells transfected with human wild-type APP
(APPwt), APP-Thr668Ala, and APP-Thr668Glu. APP was detected with an
antibody to the human protein that minimally cross-reacts with mouse
APP (6E10). Note the increased presence of JIP-1 at the terminals of the
cells transfected with APP-Thr668Glu (L–O, long arrows), but not APP–
Thr668Ala (P–R, arrows). Short arrows in (L and M) point to the terminals
of nontransfected cells. (V) Additional examples of immunolabeled neurite
terminals of transfected cells, shown at high magnification. Bars: (B–H)
and (L–U) 40  m; (I–K) 20  m; (V) 10  m. 
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and pAPP are cotransported by kinesin-1 as a complex. Phos-
phorylation of APP facilitates the formation and the transport
of this complex, as well as an overall vesicular traffic that
likely promotes the extension of neurites.
Finally, because increased availability of JIP-1 promoted
transport of pAPP, we tested whether reduction in JIP-1 impairs
transport of pAPP into neurites, i.e., whether JIP-1 is necessary
for pAPP transport. We examined the distribution of pAPP in
cells where JIP-1 expression was reduced by small interfering
RNA (siRNA), a procedure that effectively decreased the level
of endogenous JIP-1 (Fig. 5 A), as well as of JIP-1–FLAG when
cotransfected in CAD cells (Fig. 6 A). For immunocytochemistry,
JIP-1 siRNA was cotransfected with a GFP-encoding plasmid
to allow the identification of JIP-1–depleted cells. Cells trans-
fected with GFP alone, which were used as control, showed the
typical accumulation of JIP-1 at terminals (Fig. 5, B–D). How-
ever, when cotransfected with JIP-1 siRNA, GFP was present in
cells that had low levels of JIP-1 and lacked JIP-1 accumulation
at neurite terminals (Fig. 5, E–G). With regard to pAPP, cells
expressing GFP alone had normal, strong pAPP staining at the
terminals, but only low staining in the cell body (Fig. 5, H and I).
By contrast, CAD cells where JIP-1 expression was targeted by
siRNA (Fig. 5, J and K) failed to accumulate pAPP at the termi-
nals; instead, vesicles containing pAPP often accumulated in
the cell body, suggesting a deficient transport of pAPP into neu-
rites (Fig. 5, J and K, insets). This strong effect on transport was
specific for pAPP because JIP-1 depletion did not alter the lo-
calization of total, mostly nonphosphorylated, APP in neurites
(Fig. 5, L and M). Statistically, we found that 
 
 
 
20% of siRNA-
transfected cells that extended neurites contained pAPP at their
terminals, a 4.5-fold reduction compared with untreated cells.
This was similar to the fraction of siRNA-transfected cells that
had detectable JIP-1 at terminals.
Transport of pAPP to neurite terminals in cells transfected
with JIP-1 siRNA was restored by cotransfection of human
JIP-1, a form that is not down-regulated by the mouse JIP-1
siRNA (Fig. 6). This result rules out the possibility that pAPP
transport is indirectly suppressed in siRNA-transfected cells
and confirms the role of JIP-1 in pAPP transport.
Accumulation of pAPP in the cell body upon treatment of
cells with JIP-1 siRNA (see example in Fig. 5 [J and K, insets])
suggests that down-regulation of JIP-1 only affects the transport,
but not the generation, of pAPP. We conclude that JIP-1 is re-
quired for the transport of pAPP into neurites, whereas the trans-
port of nonphosphorylated APP appears independent of JIP-1.
Figure 5. JIP-1 is required for the accumulation of pAPP in neurites. (A–G)
Down-regulation of JIP-1 by siRNA. CAD cells were transfected with GFP
cDNA with or without JIP-1–specific siRNA and analyzed by immuno-
blotting (A) and immunocytochemistry (B–G) for JIP-1 expression. Transfers
of cell lysates were probed with anti–JIP-1 antibody, which detects one
polypeptide in CAD cells (A). (A) Before blotting, transfers were stained with
Ponceau S to compare protein loads. Molecular size markers are in kilo-
daltons. In immunofluorescence, cells transfected with GFP alone (control)
accumulated JIP-1 at terminals (B–D; long arrows in D), similar to nontrans-
fected cells (D, short arrows). No JIP-1 is detected at neurite endings (E–G,
long arrows) in cells cotransfected with GFP and JIP-1–specific siRNA. (E–G)
Short arrows point to terminals of nontransfected cells. Only the left portion
of the image in D is shown in B and C. (B–D) The asterisks mark correspond-
ing regions. (H–M) Down-regulation of JIP-1 leads to diminished accumula-
tion of pAPP (J and K) but not total, mostly nonphosphorylated APP (L and M)
in neurites. CAD cells were transfected with GFP alone (H and I; control) or
with GFP and JIP-1–specific siRNA (J–M). Note that down-regulation of JIP-1
occasionally leads to accumulation of pAPP in the cell body (J and K, arrow-
heads in insets), likely because of impaired pAPP transport. pAPP localizes
normally, at neurite endings, in cells transfected with GFP alone (H and I).
Arrows point to process terminals. Bars, 20  m.
Figure 6. Complementation of JIP-1–deficient CAD cells with human JIP-1
restores pAPP transport into neurites. (A) Down-regulation of mouse JIP-1
(mJIP-1) but not human JIP-1 (hJIP-1) by mJIP-1–specific siRNA. CAD cells
were transfected with FLAG-tagged mJIP-1 or hJIP-1 cDNA with or without
mJIP-1–specific siRNA. Cell lysates were analyzed for expression of exog-
enous JIP-1 by immunoblotting with anti-FLAG antibody. The actin blot
shows equal protein load. Note that mJIP-1–specific siRNA does not down-
regulate hJIP-1 (right). (B–E) Rescue of pAPP transport by hJIP-1 in mJIP-1–
deficient cells. CAD cells were transfected with GFP (B), GFP and mJIP-1–
specific siRNA (C), or GFP, mJIP-1–specific siRNA, and hJIP-1–FLAG (D
and E) and analyzed by immunocytochemistry for pAPP. Note that transfec-
tion with GFP alone does not affect localization of pAPP (B), whereas
cotransfection with mJIP-1–specific siRNA eliminates accumulation of pAPP
at neurite terminals (C). However, accumulation of pAPP at neurite endings
is restored in cells transfected with hJIP-1 in addition to GFP and mJIP-1–
specific siRNA (D and E). Long and short arrows point to the terminals of
transfected and nontransfected cells, respectively. Bar, 50  m. 
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JIP-2 can facilitate, but is not normally 
required for, accumulation of pAPP in 
neurites
 
These results indirectly suggest that JIP-2 (which also binds
pAPP; Fig. 2 B) may play at best only a minor role in the trans-
port of pAPP into neurites. We confirmed this hypothesis, using
a similar experimental strategy based on immunolocalization of
endogenous JIP-2 and pAPP, down-regulation of JIP-2 by
siRNA, and overexpression of tagged JIP-2. Thus, in immuno-
cytochemistry, JIP-2 showed an overall distribution pattern that
differed from the distribution pattern of both JIP-1 and pAPP,
particularly in the amount that entered the processes. Most JIP-2
was localized to the cell body and often only partially colocal-
ized with JIP-1 and pAPP (Fig. S5, A–F, available at http://
www.jcb.org/cgi/content/full/jcb.200502043/DC1). However,
we did occasionally see a high degree of colocalization of JIP-2
with JIP-1 at neurite terminals (Fig. S5, A–C), but significantly
less frequently than in the case of pAPP with JIP-1 (Fig. S5, G
and H). Unlike for JIP-1, down-regulation of JIP-2 expression
by siRNA (Fig. S5, I–L) did not prevent accumulation of pAPP
at neurite endings (Fig. S5, M–O). However, as with JIP-1, the
amount of pAPP accumulated at the neurite endings increased
upon mild expression of JIP-2-FLAG (Fig. S5, P–R). We con-
clude that JIP-2 can facilitate transport of pAPP into CAD cell
neurites, but it does not do so under normal conditions, when
this function is largely performed by JIP-1.
 
Nonphosphorylated APP is transported 
into neuronal processes independent of 
pAPP
 
Together, the aforementioned results support a model where
APP transport to neurites occurs via at least two pathways: a
JIP-1–dependent route, responsible for the transport of the
small fraction of cellular APP that is phosphorylated at Thr
 
668
 
,
and a JIP-1–independent pathway that carries over the non-
phosphorylated APP, which represents the majority of cellular
APP. This model implies that nonphosphorylated APP and
pAPP should be associated with different vesicle populations.
Indeed, immunocytochemistry of CAD cells shows a large
fraction of APP in vesicles where pAPP was undetectable
(Fig. 7, A–C). This segregation of nonphosphorylated APP
from pAPP was also found in primary cultures of cortical neu-
rons (Fig. 7 D), as well as in CAD cells that express APP-YFP
(Fig. 7, E–H). Quantitatively, 
 
 
 
80% of the total APP is present
in vesicles lacking detectable pAPP. This result is not due to a
failure of the antibodies to detect pAPP and nonphosphorylated
APP simultaneously on the same vesicle because in cells trans-
fected with APP-Thr668Glu, which is a mutant that is recog-
nized by both the anti-APP and anti-pAPP antibodies, we
found complete colocalization of pAPP and total APP (Fig. 7,
I–K). This is certainly because of the fact that the phosphomi-
metic APP species is predominant. Thus, our results support
the notion that pAPP and nonphosphorylated APP are largely
segregated in separate transport vesicles.
Because the antibody to APP recognizes total (phosphor-
ylated and nonphosphorylated) APP, we cannot exclude the
possibility that some nonphosphorylated APP might be co-
transported with pAPP. However, the majority of nonphosphory-
lated APP is localized to carrier vesicles that do not contain
pAPP. We conclude that phosphorylated and nonphosphorylated
APP are transported into neuronal processes by different
pathways (both likely using kinesin-1) and that, under physio-
logical conditions, JIP-1 mediates transport of pAPP, but not
nonphosphorylated APP.
 
Discussion
 
APP and JIP-1 have been shown to be transported to neuronal
terminals, where they might accomplish signaling functions,
with possible implication in the pathobiology of Alzheimer’s
disease. To investigate their transport, we have studied the lo-
calization of endogenous JIP-1, total APP, and pAPP in CAD
cells, and in primary cultures of hippocampal and cortical neu-
rons, under conditions of normal differentiation, and under ex-
perimental circumstances aimed at interfering with recruitment
to the cargo of kinesin-1. Because the localization of JIP-1,
Figure 7. Nonphosphorylated APP is largely segregated from pAPP during
transport. (A–D) Double labeling of endogenous, total APP (antibody
4G8; green) and pAPP (red) in CAD cells (A–C) and cortical neurons (D).
Note that the antibody to total APP largely labels vesicles that do not stain
for pAPP. The CAD cells shown in E–H and I–K have been transfected with
APP-YFP (wild type) and nontagged APP-Thr668Glu (APP-T668E), respec-
tively. Antibodies to total APP and pAPP label the same vesicle population
in cells transfected with APP-Thr668Glu, where the constitutively phos-
phorylated APP predominates (I–K). This situation differs from the endoge-
nous condition (nontransfected cells; A–D) or APP-YFP transfected cells
(E–H), where only a fraction of APP is phosphorylated and sorted away
from nonphosphorylated APP into distinct transport vesicles. Note that the
antibody to pAPP cross-reacts with APP-Thr668Glu (I–K). H is an enlarge-
ment of the boxed area in G. Bars: (A–H) 10  m; (I–K) 5  m. 
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total APP, and pAPP at neurite terminals is largely the result of
active anterograde transport, this experimental approach al-
lowed us to gain insight into the mechanism of this process. We
found that in situ APP transport to terminals occurs via two
separate populations of vesicles that—as detected by immuno-
cytochemistry—differ in composition and whose transport is
differentially regulated. Thus, 
 
 
 
80% of the APP-labeled ve-
sicular structures along the neurites appear to carry only non-
phosphorylated APP because they do not stain for pAPP;
these vesicles also lack JIP-1. The transport of this vesicle pop-
ulation to the neurite terminal is independent of JIP-1. The re-
maining APP-containing vesicles (
 
 
 
20%) stain for pAPP and
for JIP-1, and their transport to the terminal requires JIP-1.
Taking into account the increased affinity of JIP-1 for pAPP
over nonphosphorylated APP, these observations suggest that
selective phosphorylation of a fraction of APP in the cell body
triggers recruitment of JIP-1 to pAPP-containing vesicles,
which then facilitates binding and/or activation of kinesin-1.
The end result is the transport of pAPP–JIP-1–containing vesi-
cles to the neurite terminals, which is where they accumulate.
This process, unlike the seemingly constitutive transport of
nonphosphorylated APP, appears to be the subject of at least
two levels of regulation: the generation of pAPP and the re-
cruitment of JIP-1. From a physiological point of view, these
two levels of regulation would provide a stringent control for
the availability of the putative pAPP–JIP-1 signaling complex
at the neurite terminals.
Our immunocytochemical approach addresses the in situ
situation, which is unaffected by protein overexpression.
Because cells were fixed during a time of robust neurite exten-
sion, it is most likely that vesicles seen along the processes
were engaged in anterograde transport. Indeed, we have shown
that in CAD cells that express low levels of APP-YFP, 
 
 
 
80%
of the fluorescently labeled, motile vesicles moved antero-
gradely (Fig. S1) and, over extended periods of time, most of
the fluorescently tagged vesicles were motile (
 
 
 
70%).
We found that JIP-1 is vesicle associated and colocalizes
strictly with pAPP, but not with nonphosphorylated APP. It is
intriguing that although JIP-1 is capable of binding to nonphos-
phorylated APP in vitro or when the two proteins are overex-
pressed in heterologous systems, endogenous JIP-1 apparently
does not do so within neurites of cultured neurons in situ, where
it colocalizes exclusively with pAPP. Our biochemical data con-
firm the ability of JIP-1 to interact with nonphosphorylated APP;
however, we find that this binding is enhanced upon APP phos-
phorylation. Similarly, JIP-2 is capable of binding to pAPP in
biochemical assays. Yet, it does not appear to play a major role
in pAPP transport in vivo. The apparent discrepancy between
the results obtained by in vitro biochemical assays and those
from immunocytochemistry of endogenous proteins (where the
interaction of JIP-1 to the nonphosphorylated APP is undetect-
able) might be accounted for by the complexity of the system in
vivo. For example, in vivo JIP-1 might be prevented from bind-
ing to nonphosphorylated APP by other proteins (e.g., Fe65; Fig.
2 C) that may selectively bind to and block the JIP-1 binding site
in nonphosphorylated APP. Technical advances will allow
collection of data that accurately reflect the in vivo processes.
Schematically, we created several likely (Fig. 8, A–C)
and unlikely (Fig. 8, D–F) scenarios that fit our data regarding
the interdependent transport of nonphosphorylated APP, pAPP,
and JIP-1. The first two models (Fig. 8, A and B) emphasize
the recruitment/activation of kinesin-1 by the pAPP–JIP-1
complex. The third model (Fig. 8 C), although in line with our
results requiring the presence of JIP-1 on pAPP-containing
vesicles, takes into account the possibility that the JIP-1–kine-
sin-1 complex might be recruited to other vesicle proteins, such
as ApoER2 (Stockinger et al., 2000; Verhey et al., 2001). Con-
sistent with our observation that down-regulation of JIP-1
blocks transport of pAPP into neurites, in all these models
(Fig. 8, A–C) JIP-1 appears essential for the recruitment or ac-
tivation of kinesin-1. The diagrams in Fig. 8 (D–F) represent
situations that are not supported by our experimental results:
transport of pAPP in the absence of JIP-1 (Fig. 8 D) and trans-
port of nonphosphorylated APP with JIP-1 (Fig. 8, E and F).
In a separate study, we found that in differentiating CAD
cells, APP is primarily phosphorylated by JNK, a kinase that
binds to JIP-1 (Muresan and Muresan, 2005). Surprisingly, an-
choring of JNK to APP via JIP-1—a potential mechanism for
recruiting JNK to APP—does not appear to be required for
APP phosphorylation because APP is still phosphorylated
when JIP-1 expression is ablated by siRNA. Indeed, we re-
cently reported that JIP-3, a JNK scaffolding protein unrelated
to JIP-1, facilitates APP phosphorylation through a signaling
pathway that specifically targets APP (Muresan and Muresan,
2005). Yet, JIP-1 seems to be essential for the transport of the
already phosphorylated APP, as indicated by RNA interference
experiments. Overall, our cumulative studies indicate that JIP-1
and JIP-3 are cotransported into neurites together with pAPP
and accumulate as a complex at the growth cone. The coordi-
nated action of these two JNK scaffolding proteins, resulting in
APP phosphorylation and transport of the generated pAPP to
the leading edge of extending neurites, is consistent with a
Figure 8. Schematic representation of cotransport of JIP-1 and pAPP.
The diagram shows likely (i.e., experimentally supported; A–C) and unlikely
(D–F) scenarios for transport of JIP-1, pAPP, and nonphosphorylated APP.
(C) Kinesin-1 may bind to either pAPP or JIP-1. In vivo, pAPP is not trans-
ported without JIP-1 (D), and JIP-1 is not cotransported with nonphosphory-
lated APP (E and F). 
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function of this large signaling complex in neurite growth
(Ando et al., 1999; Muresan and Muresan, 2005). Further stud-
ies are required to elucidate the mechanisms by which APP,
JIP-3, and JIP-1 may integrate JNK signaling with vesicular
transport by kinesin-1 and neuronal differentiation.
Finally, our data suggest that a significant fraction of
APP is transported to neurite terminals in a nonphosphorylated
form, independently of pAPP and of JIP-1. Transport of non-
phosphorylated APP may occur autonomously (i.e., constitu-
tive) or in conjunction with other proteins that may bind to the
cytoplasmic domain of APP, such as Fe65 or X11
 
 
 
/Mint-1
(i.e., regulated). Our data from experiments using a dominant-
negative KLC domain that interferes with cargo binding are
consistent with a role of kinesin-1 in the transport of nonphos-
phorylated APP as well. These results need to be cautiously
interpreted because malfunction of kinesin-1 may indirectly
impede the transport of APP, even if it was not the motor that
carries the APP-containing vesicle. In the case of pAPP, how-
ever, our data argue strongly in favor of a JIP-1–facilitated
recruitment of kinesin-1 to the cargo vesicle.
It is generally admitted that a deficient axonal transport
may be one of the causes of Alzheimer’s disease (Roy et al.,
2005; Stokin et al., 2005). However, whether this may directly
involve APP as a linker for kinesin-1, as previously proposed
(Kamal et al., 2000), is currently highly debated, particularly
because pull-down and coimmunoprecipitation experiments
used to test the APP–kinesin-1 interaction are plagued by non-
specific binding (Matsuda et al., 2003; Lazarov et al., 2005).
Moreover, the endogenous conditions are not faithfully repro-
duced after cell lysis or by overexpressing proteins that change
the equilibrium between multiple, cross-interacting partners.
We believe that the current debate will only be settled by ad-
dressing the transport of APP in experimental settings that are
as close as possible to the endogenous conditions.
In conclusion, we found that transport of a fraction of
APP by kinesin-1 occurs in concert with JIP-1, and this trans-
port is regulated by the phosphorylation of APP. This implies
that transport of JIP-1 is regulated by APP phosphorylation.
Nonphosphorylated APP is transported on a different pathway,
either through a direct interaction with the kinesin motor or by
a yet to be identified mechanism. The two transport pathways
appear to use distinct vesicle carriers and to be differently regu-
lated. Further studies are required to fully understand the func-
tional significance of pAPP–JIP-1 cotransport, likely relating
these two proteins in a common signaling pathway.
 
Materials and methods
 
Antibodies
 
The following primary antibodies were used: mouse anti-Alzheimer precur-
sor protein A4 (clone 22C11; CHEMICON International, Inc.); mouse
anti–human amyloid-
 
 
 
 protein (clones 4G8 and 6E10; Signet Laborato-
ries); rabbit anti-APP (raised against a polypeptide from the cytoplasmic
domain of APP; Cell Signaling Technology); mouse anti–human APP
(mAbP2-1; BioSource International, Inc.); and mouse anti-KHC (clone H2;
CHEMICON International, Inc.). The following anti–JIP-1 and anti–JIP-2
antibodies were used: goat (E-19) and mouse (B-7) anti–JIP-1; goat (C-20)
and rabbit (H-95) anti–JIP-2 (all obtained from Santa Cruz Biotechnology,
Inc.); and rabbit anti–JIP-1 (a gift from K. Verhey and B. Margolis, Univer-
sity of Michigan, Ann Arbor, MI; Meyer et al., 1999). A mouse antibody
to KLC (63-90; Stenoien and Brady, 1997) was a gift from S. Brady
(University of Illinois, Chicago, IL). A mouse antibody (K2.4) to kinesin-2
(detecting the 85-kD polypeptide corresponding to mammalian KIF3A;
Cole et al., 1993) was a gift from J. Scholey (University of California,
Davis, Davis, CA). A rabbit antibody to pAPP (BioSource International,
Inc.) was raised against a phosphopeptide derived from the region sur-
rounding Thr
 
668
 
 of human APP695, adsorbed against the nonphosphory-
lated peptide, and affinity purified with the antigen by the manufacturer.
The antibody reacted with phosphorylated, but not with nonphosphory-
lated, forms of APP. Mouse antibodies to tags were used: anti–c-myc
(Oncogene Research Products) and anti-FLAG (M2; Stratagene).
 
Cell cultures
 
The mouse central nervous system–derived catecholaminergic cell line
CAD (obtained from D. Chikaraishi  [Duke University Medical School,
Durham, NC] and J. Wang [Cogent Neuroscience, Inc., Durham, NC]; Qi
et al., 1997) was grown in 1:1 F12/DME medium, with 8% FBS and pen-
icillin/streptomycin. CAD cell differentiation was induced by the removal
of serum from the culture medium (Qi et al., 1997). Embrynic day 16.5
mouse cortical neurons (obtained from S. Cicero and K. Herrup, Case
Western Reserve University, Cleveland, OH) were grown in neurobasal
medium with B-27 supplement, 
 
L
 
-glutamine, and penicillin/streptomycin for
5 d, with a change of media on day 4. Neurons were maintained in
growth media until fixation for immunocytochemistry. COS-1 cells were
grown in high-glucose DME, containing 10% FBS and penicillin/strepto-
mycin. HEK293 cells were grown in RPMI 1640 containing 8% FBS.
 
Transfection
 
CAD, HEK293, and COS-1 cells were transfected according to the man-
ufacturer’s instructions, using either FuGene 6 (Roche Diagnostics) or
Nucleofector technology (Amaxa Inc.). The HA-tagged KLC-TPR construct
(containing all six TPRs) and the HA-PP5-TPR construct were previously de-
scribed (Verhey et al., 2001). Constructs in pcDNA3 of human APP695
(wild-type and mutants [APP-Thr668Ala and APP-Thr668Glu]) were ob-
tained from L.-H. Tsai (Harvard Medical School, Howard Hughes Medical
Institute, Boston, MA). JIP constructs (pcMV-FLAG-JIP-1, pcDNA3-FLAG-JIP-2,
and pcDNA3-FLAG-JIP-3) were obtained from R. Davis (University of Mas-
sachusetts Medical School, Howard Hughes Medical Institute, Worcester,
MA; Whitmarsh et al., 1998; Yasuda et al., 1999; Kelkar et al., 2000).
FLAG-tagged, human JIP-1e, and mouse JIP-1b constructs were obtained
from L. D’Adamio (Albert Einstein College of Medicine, Bronx, NY; Schein-
feld et al., 2002). Myc-tagged Fe65 was obtained from B. Margolis
(University of Michigan, Howard Hughes Medical Institute, Ann Arbor, MI;
Borg et al., 1996). A pcDNA3/APP-YFP (human APP695) construct was
obtained from C. Dotti (Cavalieri Ottolenghi Scientific Institute, Università
degli Studi di Torino, Torino, Italy) and C. Kaether (European Molecular
Biology Laboratory, Heidelberg, Germany; Kaether et al., 2000).
 
RNA interference experiments
 
For immunocytochemistry, CAD cells were cotransfected with pmaxGFP
(Amaxa Inc.) and either mouse JIP-1–specific (Santa Cruz Biotechnology,
Inc.) or JIP-2–specific (Ambion) siRNA. In JIP-1 complementation experi-
ments, cells were cotransfected with pmaxGFP, human JIP-1, and mouse
JIP-1–specific siRNA. Cells were allowed to attach to the coverslip in the
presence of serum and cultured for 24–48 h in the absence of serum. For
biochemistry experiments, cells were transfected with either pmaxGFP or
FLAG-tagged JIP-1 (mouse or human) in the presence or absence of JIP-1–
specific siRNA. After differentiation, cells were collected in sample buffer
and analyzed by Western blotting for expressed proteins.
 
Pull-down and coimmunoprecipitation experiments
 
COS-1 cells transfected with cDNAs encoding FLAG-tagged JIPs were
rinsed with phosphate-buffered saline and extracted after 30 min at 4
 
 
 
C in
lysis buffer (10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 4 mM EDTA, and 1%
NP-40) containing leupeptin, pepstatin, aprotinin (10 
 
 
 
g/ml each), 5 mM
benzamidin, 1 mM PMSF, and phosphatase inhibitors (1 mM Na vana-
date, 5 mM NaF, and 25 mM 
 
 
 
-glycerophosphate). Extracts were centri-
fuged for 10 min at 16,000 
 
g
 
 and incubated 12–16 h at 4
 
 
 
C with NH
 
2
 
-
terminally biotinylated polypeptides corresponding to the entire cytoplas-
mic domain of APP (starting with lysine) that were chemically synthesized
with either phosphorylated or nonphosphorylated Thr (corresponding to
Thr
 
668
 
 in APP695). Protein complexes containing the polypeptides were
collected on streptavidin-Sepharose and analyzed by SDS-PAGE and
immunoblotting (Muresan et al., 2000) with anti-tag antibodies. Poly-
peptides corresponding to the APP cytoplasmic domain were separated in
16.5% Tris-tricine gels (Bio-Rad Laboratories). 
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In immunoprecipitation experiments that tested the role of JIP-1 in
the recruitment of kinesin-1 to APP, CAD cells were separately transfected
with human APP-Thr668Glu (or APP–Thr668Ala) and JIP-1–FLAG. Extracts
of APP-transfected cells were mixed with extracts from JIP-1–transfected or
nontransfected cells and incubated for 2 h at 4
 
 
 
C with a purified fraction
of squid kinesin-1 (Muresan et al., 1996). APP was immunoprecipitated
from the incubation mixtures with the antibody mAbP2-1 overnight at 4 C.
In experiments that tested the interaction of JIP-1 with APP and pAPP, CAD
cells were separately transfected with human APP695 and JIP-1–FLAG.
Cell extracts were mixed and incubated overnight in the presence of phos-
phatase inhibitors. JIP-1 and associated proteins were immunoprecipitated
from the mixture with anti-FLAG antibody. In control experiments, JIP-1–
FLAG–containing cytosol was replaced with cytosol from nontransfected
cells. In all cases, the collection of immunoprecipitated material on pro-
tein A–Sepharose-4B and extraction of the beads in SDS-PAGE sample
buffer was done as previously described (Muresan and Arvan, 1997). Im-
munoprecipitated material was analyzed by Western blotting. Image soft-
ware (National Institutes of Health) was used for densitometric analysis of im-
munoblots. In all immunoprecipitation experiments, extracts that contained
low levels of JIP-1–FLAG were used.
ELISA
Biotinylated APP polypeptides (with phosphorylated or nonphosphorylated
Thr
668) were adsorbed to Reacti-Bind NeutrAvidin-coated Plates that were
preblocked with SuperBlock Blocking Buffer (Pierce Chemical Co.). Cyto-
solic fractions containing increasing levels of JIP-1–FLAG or Fe65-myc
were prepared by mixing decreasing volumes of cytosol from nontrans-
fected HEK293 cells with increasing volumes of cytosol from transfected
cells. Cytosol concentration was thus kept constant throughout the assay.
The plates were incubated with these fractions, then with alkaline phos-
phatase–conjugated antibodies to FLAG or myc, and processed for colori-
metric reaction, followed by an OD reading at 405 nm, according to the
manufacturer’s protocol.
Preparation of brain extracts
Brain tissue was collected from neonatal (P2) or 5-week-old male Sprague-
Dawley rats (killed by asphyxiation with CO2; protocol approved by the
Institutional Animal Care and Use Committee at Case Western Reserve
University), placed in ice-cold phosphate-buffered saline, pH 7.4, and ho-
mogenized in Hepes–acetate buffer (50 mM K-Hepes, 50 mM K-acetate,
5 mM EGTA, 5 mM Mg acetate, 1 mM Na vanadate, 5 mM NaF, and 25
mM  -glycerophosphate, pH 7.4) containing protease inhibitors. Extracts
were analyzed for the presence of JIP-1, APP, and pAPP by Western blot-
ting. Incubations with anti-pAPP antibodies were done in the presence or
absence of competitor polypeptides (i.e., biotinylated, phosphorylated, or
nonphosphorylated polypeptides that encompassed the entire APP cyto-
plasmic domain) at 100:1 molar excess over IgG.
Immunocytochemistry
Transfected or nontransfected CAD cells and primary cultures of cortical
neurons were fixed for 20 min in phosphate-buffered saline containing 4%
formaldehyde and 4% sucrose, permeabilized with 0.3% Triton X-100 for
20 min at 20 C, and processed for single or double antigen labeling as
previously described (Muresan et al., 1998). Secondary antibodies (goat
anti–mouse/rabbit IgG or donkey anti–goat/mouse/rabbit IgG) coupled
to Alexa dyes (Alexa Fluor 488 and Alexa Fluor 594) were obtained from
Invitrogen. When required, double labeling experiments with two primary
antibodies raised in rabbit were done using fluorescently labeled, monova-
lent Fab fragments of anti–rabbit IgG (Jackson ImmunoResearch Laborato-
ries; Li et al., 2002). In control experiments, immunolabeling with anti-pAPP
antibody was done in the presence of phosphorylated or nonphosphory-
lated polypeptides (100:1 molar excess over IgG) that encompassed either
a 12–amino acid region centered on Thr
668 or the entire APP cytoplasmic
domain. Transfected human APP was selectively detected with antibody
6E10 that does not detect endogenous mouse APP. Unless otherwise spec-
ified, endogenous JIP-1 and total APP were detected with goat polyclonal
and mouse monoclonal (4G8) antibodies, respectively. Digital images
were obtained with two different microscopes (Model Axiophot; Carl
Zeiss MicroImaging, Inc.; or model Optiphot; Nikon; 100  oil, 20 , and
40  objectives) equipped with cooled charge-coupled device cameras
(Olympus) and collected using either Openlab (Improvision Inc.) or
Magnafire (Optronics) image analysis software. Images were processed
for contrast and brightness using Photoshop software (Adobe). In some
cases, samples were analyzed by confocal microscopy; in others, images
were collected on a microscope (DeltaVision RT) and subjected to decon-
volution analysis.
In vivo motility
Motility of APP-YFP–containing vesicles was visualized in vivo, in thin pro-
cesses of transiently transfected CAD cells. The experimental set-up con-
sisted of an inverted microscope (model TE200U; Nikon), a camera
(model CoolSnapHQ; Roper), and MetaMorph software (Molecular De-
vices). Kymographs (Silverman et al., 2001) were generated from successive
images acquired at 0.502 frames/s and used for quantifying anterograde
and retrograde motile and stationary vesicles.
Quantitative analysis
The degree of colocalization of various antigen pairs was quantified as
follows. First, the mean pixel intensity for each pair of images was deter-
mined in Photoshop 7.0 (Adobe; Sabo et al., 2003). Second, images
were thresholded at the mean intensity, to eliminate most of the diffuse,
nonparticulate labeling. Finally, the thresholded images were multiplied.
The resulting image showed nonzero pixel intensities only in regions of
colocalization, i.e., regions were pixel intensity differed from zero in both
images. Percentages of colocalization were calculated by dividing the
number of pixels of nonzero intensities in the product image by the num-
ber of pixels of nonzero intensities in the parental images.
In experiments that probed pAPP localization in cells transfected
with JIP-1–FLAG or Fe65-myc, coefficients of colocalization of pAPP with
the tagged proteins were obtained using Image-Pro Plus software (Media
Cybernetics, Inc.; Manders et al., 1993). The percentage of transfected
cells that showed increased pAPP at neurite terminals was estimated by
comparison with nontransfected cells present in the microscopic field. For
each experiment, 20–30 microscopic fields, each containing at least one
transfected cell expressing the tagged protein at a low level, were ana-
lyzed. Cells were judged as expressing low levels of JIP-1–FLAG if cell
bodies contained little tagged protein compared with the processes.
Experiments with JIP-1–FLAG–transfected cells were done in duplicate.
Online supplemental material
Fig. S1 shows that most of the fluorescently labeled vesicles move antero-
gradely within neurites of CAD cells transfected with APP-YFP. Fig. S2
characterizes by Western blotting and immunocytochemistry the main an-
tibodies used in this study and shows specificity of the anti-pAPP antibody
strictly for pAPP. Fig. S3 shows colocalization of pAPP with microtubules
and kinesin-1, but not kinesin-2, in CAD cell processes. Fig. S4 shows that
localization of total APP to neurites is kinesin-1 dependent. Fig. S5 shows
that JIP-2 is not required for the accumulation of pAPP in neurites. Online
supplemental material is available at http://www.jcb.org/cgi/content/
full/jcb.200502043/DC1.
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